Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (VERA) is a clinical-stage biotechnology company pioneering targeted therapies for autoimmune and inflammatory diseases. This page provides investors and stakeholders with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access Vera Therapeutics' latest press releases, including progress reports on atacicept for IgA nephropathy (IgAN) and lupus nephritis, updates on its MAU868 antibody program, and strategic partnerships. Our curated news feed ensures you stay informed about pivotal Phase 3 trial results, FDA communications, and financial disclosures that may impact investment decisions.
Key coverage areas include B cell modulation research, clinical trial design innovations, and collaborations with leading medical institutions. Bookmark this page for direct access to primary source materials and analysis-free reporting on Vera's scientific advancements in immunological therapeutics.
Vera Therapeutics announced on July 5, 2024, that it has granted inducement awards under Nasdaq Listing Rule 5635(c)(4) to new employees, including the newly appointed COO, David Johnson. The grants, approved by the Compensation Committee, include non-qualified stock options to purchase 160,000 shares for Johnson and additional inducement awards of 139,100 stock options and 61,925 restricted stock units (RSUs) to ten new employees. The exercise prices for the stock options are $36.29 and $34.93, corresponding to the closing trading prices on the respective grant dates of July 1 and July 2, 2024. The options and RSUs will vest over four years, contingent upon continuous service. These awards are a strategic incentive to attract top talent to Vera Therapeutics.
Vera Therapeutics announced the immediate appointment of David L. Johnson as Chief Operating Officer. Johnson brings over 30 years of experience in the biopharmaceutical industry, including key roles at Global Blood Therapeutics and Gilead Sciences. He will oversee the commercialization efforts for atacicept, a treatment for IgAN, which is currently in Phase 2b and Phase 3 clinical trials. CEO Marshall Fordyce highlighted Johnson's expertise in successful commercial launches as important for the potential launch of atacicept. Johnson expressed enthusiasm for advancing atacicept, noting its promising clinical data and potential to be among the first approved B cell modulators for IgAN.
Vera Therapeutics has appointed Christy J. Oliger to its board of directors, effective June 7, 2024. Oliger brings over 30 years of experience in the biopharmaceutical industry, having led significant commercial product launches and built highly effective teams. She currently serves on the boards of Karyopharm Therapeutics, Replimune Group, and LAVA Therapeutics, and has past board experience with Sierra Oncology, Reata Pharmaceuticals, and RayzeBio. Oliger’s extensive experience will support Vera's advancement of atacicept for IgAN treatment and its potential commercial launch.
On June 4, 2024, Vera Therapeutics granted inducement awards to five new employees under its 2024 Inducement Plan. These awards include non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units (RSUs) for 14,500 shares. The stock options have an exercise price of $39.47 per share, matching Vera’s closing price on that date. The stock options and RSUs vest over four years with specific conditions attached. These grants were approved by Vera's Compensation Committee in adherence to Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Vera Therapeutics, a late clinical-stage biotechnology company, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will occur from June 10-13, 2024, at the Loews Miami Beach Hotel.
CEO Marshall Fordyce, M.D., will present on June 12 at 10:40 AM EDT, and the management team will engage in one-on-one investor meetings.
Vera Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to its drug atacicept for the treatment of Immunoglobulin A Nephropathy (IgAN). This decision is based on data from a Phase 2b ORIGIN trial, showing atacicept's potential to significantly improve kidney function as measured by eGFR over existing treatments. The company plans to release long-term results from this trial later in 2024 and expects Phase 3 trial results in the first half of 2025, which will support its regulatory approval submission.
Vera Therapeutics announced positive results from its Phase 2b ORIGIN trial of atacicept in treating IgA nephropathy (IgAN) at the 61st European Renal Association Congress. Over 72 weeks, atacicept showed stable kidney function, rapid, and sustained improvements in hematuria compared to placebo. The study revealed a 91% retention rate, enhancing the drug's safety profile. Additionally, atacicept led to significant reductions in Gd-IgA1, hematuria, and UPCR in participants. Vera aims to present 96-week data in Q4 2024 and expects Phase 3 enrollment completion by Q3 2024, with primary endpoint data by H1 2025.
Vera Therapeutics, a biotechnology company, shared positive 72-week data from its Phase 2b ORIGIN clinical trial for IgAN. They reported no kidney function loss with atacicept treatment. They anticipate Phase 3 ORIGIN 3 trial results in 2025. The company completed a $287.5 million financing, strengthening its financial position.
Vera Therapeutics, Inc. (Nasdaq: VERA) granted inducement awards to new employees under its 2024 Inducement Plan. The awards include non-qualified stock options and restricted stock units. The stock options have exercise prices based on Vera's closing trading prices on specific dates. The awards vest over four years, contingent on the employees' continued service with the company. These awards were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
